[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008133128A1 - 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途 - Google Patents

縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途 Download PDF

Info

Publication number
WO2008133128A1
WO2008133128A1 PCT/JP2008/057392 JP2008057392W WO2008133128A1 WO 2008133128 A1 WO2008133128 A1 WO 2008133128A1 JP 2008057392 W JP2008057392 W JP 2008057392W WO 2008133128 A1 WO2008133128 A1 WO 2008133128A1
Authority
WO
WIPO (PCT)
Prior art keywords
derivative
pharmaceutical composition
composition
fused heterocyclic
medical purposes
Prior art date
Application number
PCT/JP2008/057392
Other languages
English (en)
French (fr)
Inventor
Takashi Miyagi
Shigeru Yonekubo
Kohsuke Ohno
Mikie Kambara
Nobuhiko Fushimi
Original Assignee
Kissei Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co., Ltd. filed Critical Kissei Pharmaceutical Co., Ltd.
Priority to CA002682400A priority Critical patent/CA2682400A1/en
Priority to EP08740473A priority patent/EP2145889A4/en
Priority to US12/596,301 priority patent/US20100130514A1/en
Priority to JP2009511816A priority patent/JP5352450B2/ja
Publication of WO2008133128A1 publication Critical patent/WO2008133128A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

 本発明は、性ホルモン依存性疾患等の予防又は治療剤として有用な化合物を提供する。すなわち、下記一般式（Ｉ）で表される縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途等を提供する。式（Ｉ）中、環Ａは、５員環不飽和炭化水素又は５員環へテロアリール；ＲＡは、ハロゲン、アルキル、アルケニル、アルキニル、カルボキシ、アルコキシ、カルバモイル、アルキルカルバモイル等；環Ｂはアリール又はヘテロアリール；ＲＢは、ハロゲン、アルキル、カルボキシ、アルコキシ、カルバモイル、アルキルカルバモイル等；Ｅ１、Ｅ２は、酸素原子等；Ｕは、単結合又はアルキレン；Ｘは、Ｙ、－Ｏ－（アルキレン）－Ｙ、－Ｏ－Ｚで表される基（Ｙは、Ｚ又はＺが置換したアミノ等；Ｚは、シクロアルキル、ヘテロシクロアルキル、アリール、ヘテロアリール等）;等である。
PCT/JP2008/057392 2007-04-18 2008-04-16 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途 WO2008133128A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002682400A CA2682400A1 (en) 2007-04-18 2008-04-16 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes
EP08740473A EP2145889A4 (en) 2007-04-18 2008-04-16 HETEROCYCLIC FUSED CORE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE DERIVATIVE, AND USE OF THE COMPOSITION FOR MEDICAL PURPOSES
US12/596,301 US20100130514A1 (en) 2007-04-18 2008-04-16 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes
JP2009511816A JP5352450B2 (ja) 2007-04-18 2008-04-16 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-108944 2007-04-18
JP2007108944 2007-04-18

Publications (1)

Publication Number Publication Date
WO2008133128A1 true WO2008133128A1 (ja) 2008-11-06

Family

ID=39925584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057392 WO2008133128A1 (ja) 2007-04-18 2008-04-16 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途

Country Status (5)

Country Link
US (1) US20100130514A1 (ja)
EP (1) EP2145889A4 (ja)
JP (1) JP5352450B2 (ja)
CA (1) CA2682400A1 (ja)
WO (1) WO2008133128A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014030743A1 (ja) 2012-08-24 2014-02-27 武田薬品工業株式会社 複素環化合物
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
TWI460184B (zh) * 2011-10-25 2014-11-11 Central Glass Co Ltd Siloxanes and their hardened products and their use
WO2017038650A1 (ja) * 2015-08-28 2017-03-09 積水メディカル株式会社 ベンジル化合物
RU2769828C1 (ru) * 2021-12-28 2022-04-06 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Производные урацила, обладающие противовирусной активностью в отношении sars-cov-2

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113666943A (zh) * 2020-05-15 2021-11-19 苏州泽璟生物制药股份有限公司 氘代四氢噻吩并[3,4-d]嘧啶二酮化合物以及包含该化合物的药物组合物
CN115260211B (zh) * 2021-04-29 2024-02-06 长春金赛药业有限责任公司 含噻吩稠环类衍生物、药物组合物及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510992A (ja) 1991-09-20 1994-12-08 ビーエーエスエフ　アクチェンゲゼルシャフト 置換３−フェニルウラシル
WO1995028405A1 (en) * 1994-04-19 1995-10-26 Takeda Chemical Industries, Ltd. Bicyclic thiophene derivatives and use as gonadotropin releasing hormone antagonists
WO1996024597A1 (en) 1995-02-08 1996-08-15 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
WO2000039131A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company Nitrogen containing heterobicycles as factor xa inhibitors
WO2001055119A2 (en) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
WO2005019188A1 (ja) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
WO2006083005A1 (ja) 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
WO2007046392A1 (ja) * 2005-10-19 2007-04-26 Kissei Pharmaceutical Co., Ltd. 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121200A1 (en) * 2003-11-29 2006-06-08 Cross Match Technologies, Inc. Electroless plating of piezoelectric ceramic
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510992A (ja) 1991-09-20 1994-12-08 ビーエーエスエフ　アクチェンゲゼルシャフト 置換３−フェニルウラシル
WO1995028405A1 (en) * 1994-04-19 1995-10-26 Takeda Chemical Industries, Ltd. Bicyclic thiophene derivatives and use as gonadotropin releasing hormone antagonists
WO1996024597A1 (en) 1995-02-08 1996-08-15 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
WO2000039131A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company Nitrogen containing heterobicycles as factor xa inhibitors
US20030004167A1 (en) 1998-12-23 2003-01-02 Lam Patrick Y. Imidazo-heterobicycles as factor Xa inhibitors
WO2001055119A2 (en) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
WO2005019188A1 (ja) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
WO2006083005A1 (ja) 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
WO2007046392A1 (ja) * 2005-10-19 2007-04-26 Kissei Pharmaceutical Co., Ltd. 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Igakusyoin", article "Hyojun Seirigaku", pages: 882 - 891
HIROKAWA SYOTEN: "Molecular design", vol. 7, HIROKAWA BOOK STORE, article "lyakuhin no Kaihatsu", pages: 163 - 198
SANKA TO FUJINKA, vol. 71, no. 3, 2004, pages 280 - 285
See also references of EP2145889A4 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI460184B (zh) * 2011-10-25 2014-11-11 Central Glass Co Ltd Siloxanes and their hardened products and their use
WO2014030743A1 (ja) 2012-08-24 2014-02-27 武田薬品工業株式会社 複素環化合物
CN104755465A (zh) * 2012-08-24 2015-07-01 武田药品工业株式会社 杂环化合物
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
JPWO2014042176A1 (ja) * 2012-09-14 2016-08-18 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
JP6201076B1 (ja) * 2015-08-28 2017-09-20 積水メディカル株式会社 ベンジル化合物
WO2017038650A1 (ja) * 2015-08-28 2017-03-09 積水メディカル株式会社 ベンジル化合物
JP2018002700A (ja) * 2015-08-28 2018-01-11 積水メディカル株式会社 ベンジル化合物
KR20180044305A (ko) * 2015-08-28 2018-05-02 세키스이 메디칼 가부시키가이샤 벤질 화합물
CN108026116A (zh) * 2015-08-28 2018-05-11 积水医疗株式会社 苄基化合物
US10822357B2 (en) 2015-08-28 2020-11-03 Sekisui Medical Co., Ltd. Benzyl compound
US11591351B2 (en) 2015-08-28 2023-02-28 Sekisui Medical Co., Ltd. Benzyl compound
KR102630720B1 (ko) 2015-08-28 2024-01-29 세키스이 메디칼 가부시키가이샤 벤질 화합물
RU2769828C1 (ru) * 2021-12-28 2022-04-06 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Производные урацила, обладающие противовирусной активностью в отношении sars-cov-2

Also Published As

Publication number Publication date
US20100130514A1 (en) 2010-05-27
JP5352450B2 (ja) 2013-11-27
JPWO2008133128A1 (ja) 2010-07-22
EP2145889A1 (en) 2010-01-20
CA2682400A1 (en) 2008-11-06
EP2145889A4 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
TW200732309A (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
WO2008129994A1 (ja) 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途
WO2008133128A1 (ja) 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途
CY1121161T1 (el) Εξαμελες παραγωγο πυρρολιου ετεροαρυλικου δακτυλιου, μεθοδος παρασκευης αυτου και ιατρικες χρησεις αυτου
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
NZ593951A (en) Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
WO2007110237A3 (en) Amide derivatives and their application for the treatment of g protein related diseases
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
BRPI0507005A (pt) compostos, composições farmacêuticas, uso de um composto, e, método de preparo de uma composição farmacêutica
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
TW200833682A (en) Pharmaceutical compounds
WO2008011110A3 (en) Di-amino-substituted heterocyclic compounds and methods of use
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
MX2009003227A (es) Moduladores de los receptores de glutamato metabotropicos 5(mglur5).
WO2009142571A8 (en) Phenyl and benzodioxinyl substituted indazoles derivatives
WO2008005914A3 (en) Novel glucokinase activators and methods of using same
WO2008147557A3 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
PE20070814A1 (es) Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
MX2009004780A (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico.
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法
WO2008006795A3 (en) Indole compounds
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740473

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009511816

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2682400

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12596301

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008740473

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008740473

Country of ref document: EP